PPARA and metabolic dysfunction-associated steatohepatitis: Thus we have proposed that dual FXR/PPAR modulation might be more efficacious in NASH treatment, as PPAR- and FXR-mediated effects result from different molecular mechanisms, occur in different tissues, and could support each other in promoting therapeutic effects.